2025: A turbulent year for the biotechnology industry
CEOS of biotech companies and financial investors assess the year 2025 with a different viewpoint.
Latest
US FDA Novel Drug Approval for 2025
SPECIAL REPORT 25.18
We wish all our readers and followers a Happy and Prosperous Year 2026
US FDA Novel Drug Approval for 2025
Despite a major turmoil and an important number of resignations, the U.S FDA’s Center for Drug Evaluation and Research (CDER) indicates that the health
Welcome to jcmuller.com
Over the last twelve years, through the btobioinnovation platform, we have published around 400 news and special reports and thus developed a strong and reliable network of readers and followers.
We sincerely thank you for the trust you have placed into our former publications, and we look forward to continuing
Hommage à Ernest DUCHESNE (1874-1912)
17 décembre 1897- 17 décembre 2025
Pratiquement personne, en France, ne connaît Ernest Duchesne, médecin militaire français, né le 30 mai 1874 à Paris et décédé le 30 avril 1912 à l’hôpital des armées d’Amélie-les-Bains (où un square porte son nom) des suites d’une infection de tuberculose,
Update on Alzheimer’s disease treatments
2025 brings disappointing news for Alzheimer's patients in Europe: regulatory hurdles for new treatments and major clinical trial failures.
Le Populisme en France : Une note d’éclairage
De la défiance politique à la crise identitaire : pourquoi le populisme séduit près de 50% des Français et comment il se manifeste à droite et à gauche.
Cell and Gene Therapies: A Perspective
Cell and gene therapies promise medical breakthroughs, but manufacturing complexity, $2M price tags, and patient journey challenges force major pharma exits.